Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT04768881 · Karyopharm Therapeutics Inc · PHASE2 · terminated · last registry update 2024-08-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab.” | – | Registry record, Karyopharm Therapeutics Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XPO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-22Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS32015 + Pomalidomide (NCT07138209)
- 2025-06-10Results posted on the registry: Jennifer Woyach, Selinexor + Ibrutinib (NCT02303392)
- 2025-06-09Also stopped (terminated): Antengene Corporation, ATG-010 + Lenalidomide (NCT05265975)
- 2025-06-08Phase 3 first posted: Chengdu Zenitar Biomedical Technology Co., Ltd, Purinostat Mesylate for Injection + Selinexor Tablets (NCT07011056)
- 2025-06-04Also stopped (terminated): M.D. Anderson Cancer Center, Capecitabine + Carboplatin (NCT02419495)
- 2025-05-30Also stopped (terminated): Institute of Hematology & Blood Diseases Hospital, China, Selinexor + Venetoclax (NCT06449482)
- 2025-02-07Results posted on the registry: Antengene Corporation, ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle (NCT03992339)
- 2024-12-16Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor + Temozolomide (TMZ) (NCT04421378)
- 2024-12-16Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor + Temozolomide (TMZ) (NCT04421378)
- 2024-10-15Results posted on the registry: National Cancer Institute (NCI), Selinexor + Temozolomide (NCT04216329)
- 2024-10-09Results posted on the registry: University of Utah, Selinexor (NCT03627403)
- 2024-09-25Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Selinexor + Melphalan (NCT06613035)
- 2024-07-10Also stopped (withdrawn): Washington University School of Medicine, Selinexor + Lenalidomide (NCT05820763)
- 2024-06-13Results posted on the registry: University of Texas Southwestern Medical Center, Selinexor + Docetaxel (NCT03095612)
- 2024-06-13Also stopped (terminated): University of Texas Southwestern Medical Center, Selinexor + Docetaxel (NCT03095612)
- 2024-03-27Also stopped (withdrawn): St. Jude Children's Research Hospital, Idasanutlin + Idasanutlin (NCT05952687)
- 2024-01-08Results posted on the registry: Karyopharm Therapeutics Inc, KCP-330 (NCT01896505)
- 2024-01-02Results posted on the registry: Children's Oncology Group, Selinexor (NCT02323880)
- 2023-12-06Phase 3 first posted: AbbVie, Etentamig + Carfilzomib (NCT06158841)
- 2023-11-07Results posted on the registry: Mohammed Najeeb Al Hallak, gemcitabine hydrochloride + Selinexor (NCT02178436)
- 2023-11-03Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-11-03Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-10-25Results posted on the registry: Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
- 2023-10-25Also stopped (terminated): Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision